Q3 EPS Estimates for Nuvectis Pharma Lifted by HC Wainwright

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Equities research analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for Nuvectis Pharma in a research note issued to investors on Tuesday, August 4th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.23) per share for the quarter, up from their previous forecast of ($0.26). HC Wainwright currently has a “Buy” rating and a $39.00 price target on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.02) EPS, FY2027 earnings at ($1.10) EPS and FY2028 earnings at ($1.24) EPS.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04).

A number of other research analysts have also weighed in on NVCT. Wall Street Zen raised shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Roth Capital increased their price objective on shares of Nuvectis Pharma from $20.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvectis Pharma in a research note on Friday, June 5th. Finally, UBS Group set a $33.00 target price on Nuvectis Pharma in a report on Monday, July 6th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $35.00.

Nuvectis Pharma Price Performance

NVCT opened at $19.26 on Thursday. Nuvectis Pharma has a 1 year low of $5.55 and a 1 year high of $29.27. The company has a market capitalization of $510.97 million, a price-to-earnings ratio of -14.70 and a beta of -0.26. The firm’s fifty day moving average price is $17.02 and its two-hundred day moving average price is $11.78.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NVCT. Bank of America Corp DE raised its position in shares of Nuvectis Pharma by 10.2% in the first quarter. Bank of America Corp DE now owns 14,847 shares of the company’s stock valued at $115,000 after purchasing an additional 1,377 shares during the period. Oppenheimer & Co. Inc. lifted its stake in shares of Nuvectis Pharma by 6.5% during the 4th quarter. Oppenheimer & Co. Inc. now owns 73,566 shares of the company’s stock valued at $555,000 after buying an additional 4,500 shares in the last quarter. Barclays PLC boosted its holdings in Nuvectis Pharma by 31.3% in the 4th quarter. Barclays PLC now owns 24,185 shares of the company’s stock worth $183,000 after buying an additional 5,760 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Nuvectis Pharma by 15.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 44,022 shares of the company’s stock worth $332,000 after buying an additional 6,040 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in Nuvectis Pharma by 3,398.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after buying an additional 6,084 shares in the last quarter. Institutional investors own 96.77% of the company’s stock.

Insider Buying and Selling at Nuvectis Pharma

In other news, CEO Ron Bentsur bought 12,500 shares of the stock in a transaction on Tuesday, June 30th. The shares were purchased at an average cost of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the purchase, the chief executive officer directly owned 3,688,424 shares in the company, valued at $73,768,480. This represents a 0.34% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Marlio Charles Mosseri bought 50,000 shares of the stock in a transaction on Tuesday, June 30th. The stock was purchased at an average price of $18.32 per share, for a total transaction of $916,000.00. Following the completion of the purchase, the insider owned 3,186,576 shares of the company’s stock, valued at approximately $58,378,072.32. This trade represents a 1.59% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 28.55% of the stock is currently owned by corporate insiders.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.